81% of Clinical Trial Volunteers Suffer Reactions to CanSino Biologics’ COVID-19 Vaccine

[Collective Evolution]: COVID-19 vaccines have been in production for several months now, and clinical trials have been underway in various countries. One experimental vaccine being developed by CanSino Biologics, Inc. of Tianjin, China, has completed phase 1 of human clinical trials for COVID-19 vaccine (adenovirus type-5 Ad5-nCoV) and involved 108 volunteers, ranging in age from 45–60 years old.

Participants were given various levels of dosing, from low to high. 87 (or 81%) of the 108 participants experienced at least one adverse reaction within seven days after receiving the vaccination. Of the 87 who had reactions, 30 were in the low dose group, 30 were in the middle dose group, and 27 were in the high dose group. Overall, 10 of the participants (just under 10%) experienced Grade 3 adverse reactions, most were in the high dose group....<<<Read The Full Article Here>>>...